MX2023005408A - Compuestos y su uso en el tratamiento de trastornos mediados por el receptor de taquiquinina. - Google Patents
Compuestos y su uso en el tratamiento de trastornos mediados por el receptor de taquiquinina.Info
- Publication number
- MX2023005408A MX2023005408A MX2023005408A MX2023005408A MX2023005408A MX 2023005408 A MX2023005408 A MX 2023005408A MX 2023005408 A MX2023005408 A MX 2023005408A MX 2023005408 A MX2023005408 A MX 2023005408A MX 2023005408 A MX2023005408 A MX 2023005408A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- treatment
- receptor mediated
- mediated disorders
- tachykinin receptor
- Prior art date
Links
- 102000007124 Tachykinin Receptors Human genes 0.000 title abstract 2
- 108010072901 Tachykinin Receptors Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 102100037342 Substance-K receptor Human genes 0.000 abstract 1
- 101710116609 Substance-K receptor Proteins 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/22—Tachykinins, e.g. Eledoisins, Substance P; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20206509 | 2020-11-09 | ||
| PCT/EP2021/081057 WO2022096736A1 (en) | 2020-11-09 | 2021-11-09 | Compounds and their use in treatment of tachykinin receptor mediated disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005408A true MX2023005408A (es) | 2023-07-25 |
Family
ID=73198203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005408A MX2023005408A (es) | 2020-11-09 | 2021-11-09 | Compuestos y su uso en el tratamiento de trastornos mediados por el receptor de taquiquinina. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230406883A1 (enExample) |
| EP (1) | EP4240749A1 (enExample) |
| JP (1) | JP2023551122A (enExample) |
| KR (1) | KR20230106616A (enExample) |
| CN (1) | CN116745310A (enExample) |
| AU (1) | AU2021374843A1 (enExample) |
| CA (1) | CA3197916A1 (enExample) |
| CL (1) | CL2023001325A1 (enExample) |
| CO (1) | CO2023007404A2 (enExample) |
| IL (1) | IL302745A (enExample) |
| MX (1) | MX2023005408A (enExample) |
| PE (1) | PE20231952A1 (enExample) |
| WO (1) | WO2022096736A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240118914A (ko) | 2021-01-20 | 2024-08-05 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 질환 치료를 위한 조성물 및 방법 |
| CA3231953A1 (en) | 2021-09-15 | 2023-03-23 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| WO2023118263A1 (en) * | 2021-12-21 | 2023-06-29 | Embark Biotech Aps | Agonists for treatment of eating disorder |
| CN117384258B (zh) * | 2023-10-12 | 2024-07-26 | 湖南中晟全肽生物科技股份有限公司 | 一种神经激肽受体2（nk2r）激动剂及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2660247A3 (en) * | 2009-05-08 | 2014-09-03 | Chongxi Yu | High penetration prodrug compositions of peptides and peptide-related compounds |
| CA2918245C (en) * | 2013-08-01 | 2022-08-30 | Dignify Therapeutics, Inc. | Compositions and methods for inducing urinary voiding and defecation |
| WO2015071355A1 (en) * | 2013-11-15 | 2015-05-21 | Novo Nordisk A/S | Selective pyy compounds and uses thereof |
| MX392572B (es) * | 2015-06-12 | 2025-03-24 | Novo Nordisk As | Compuestos del péptido yy (pyy) selectivos y sus usos. |
| US11352391B2 (en) * | 2017-09-21 | 2022-06-07 | Dignify Therapeutics, Llc | Compositions for inducing urinary voiding and defecation |
| PE20210473A1 (es) * | 2018-05-04 | 2021-03-08 | Novo Nordisk As | Derivados de gip y usos de estos |
| KR20220084035A (ko) * | 2019-10-17 | 2022-06-21 | 유니버시티 오브 코펜하겐 | Tacr2의 효능제 |
-
2021
- 2021-11-09 IL IL302745A patent/IL302745A/en unknown
- 2021-11-09 CN CN202180089751.3A patent/CN116745310A/zh active Pending
- 2021-11-09 WO PCT/EP2021/081057 patent/WO2022096736A1/en not_active Ceased
- 2021-11-09 PE PE2023001563A patent/PE20231952A1/es unknown
- 2021-11-09 CA CA3197916A patent/CA3197916A1/en active Pending
- 2021-11-09 JP JP2023528102A patent/JP2023551122A/ja not_active Ceased
- 2021-11-09 AU AU2021374843A patent/AU2021374843A1/en active Pending
- 2021-11-09 MX MX2023005408A patent/MX2023005408A/es unknown
- 2021-11-09 EP EP21802379.4A patent/EP4240749A1/en active Pending
- 2021-11-09 KR KR1020237016448A patent/KR20230106616A/ko active Pending
- 2021-11-09 US US18/252,056 patent/US20230406883A1/en active Pending
-
2023
- 2023-05-08 CL CL2023001325A patent/CL2023001325A1/es unknown
- 2023-06-05 CO CONC2023/0007404A patent/CO2023007404A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20231952A1 (es) | 2023-12-06 |
| WO2022096736A1 (en) | 2022-05-12 |
| US20230406883A1 (en) | 2023-12-21 |
| CA3197916A1 (en) | 2022-05-12 |
| CL2023001325A1 (es) | 2023-12-15 |
| AU2021374843A1 (en) | 2023-06-08 |
| KR20230106616A (ko) | 2023-07-13 |
| AU2021374843A9 (en) | 2024-08-08 |
| JP2023551122A (ja) | 2023-12-07 |
| CO2023007404A2 (es) | 2023-07-10 |
| EP4240749A1 (en) | 2023-09-13 |
| IL302745A (en) | 2023-07-01 |
| CN116745310A (zh) | 2023-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201903091B (en) | Methods of treating inflammatory conditions | |
| ECSP099749A (es) | Antagonistas piridil piperidina del receptor de orexina | |
| TN2011000171A1 (en) | Isonicotinamide orexin receptor antagonists | |
| JOP20230036A1 (ar) | نواهض مستقبل أوريكسين بيروليدين سيكلوهيبتان | |
| WO2016100157A3 (en) | 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists | |
| MX2007008328A (es) | Antagonistas cxcr4 para el tratamiento de trastornos medicos. | |
| MX2009005712A (es) | Antagonistas de receptor de orexina de diazepam sustituido. | |
| WO2016100162A3 (en) | 5,5-bicyclic oxazole orexin receptor antagonists | |
| MX2020010879A (es) | Carboxamidas biciclicas y metodos de uso de las mismas. | |
| MY207469A (en) | Therapeutic compounds | |
| CO2023007404A2 (es) | Compuestos y su uso en el tratamiento de trastornos mediados por receptores de taquicinina | |
| MY196791A (en) | New tetrahydropyrimidodiazepin and dihydropyridodiazepin compounds for treating pain and pain related conditions | |
| NZ734400A (en) | Amide compounds as 5-ht4 receptor agonists | |
| AU2020288559A8 (en) | Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists | |
| MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
| MXPA06003363A (es) | Derivados de fenil-piperazina como moduladores de receptores muscarinicos. | |
| MX2020006348A (es) | Pirrolidinamidas i sustituidas. | |
| ZA202100672B (en) | Further substituted triazolo quinoxaline derivatives | |
| WO2020254552A3 (en) | Substituted pyrrolidine amides v | |
| PH12021550671A1 (en) | Prodrugs of cgrp antagonists | |
| MX2021000408A (es) | Antagonistas de los receptores p2x3. | |
| PH12020551779A1 (en) | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | |
| MX2025001279A (es) | Aril-triazolilo y antagonistas gpr84 relacionados y usos de estos | |
| ZA202211253B (en) | Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases | |
| MX2025006978A (es) | Compuestos heterociclicos y usos de los mismos |